Heterogeneity in the presentation of clinical type 1 diabetes defined by the level of risk conferred by HLA class II genotypes

The association between human leukocyte antigen (HLA) class II genotypes and susceptibility to type 1 diabetes (T1D) is well established. This study aimed at examining whether there are differences in the presentation of T1D depending on the HLA genotype. We divided the study participants (N = 5798) in the Finnish Pediatric Diabetes Register into two groups based on the T1D risk conferred by their HLA genotype (high and moderate risk genotypes, Group 1 vs. other genotypes, Group 2). We then examined differences in clinical, metabolic and immunological characteristics. Children included in the study were 0 to 14-year-old and diagnosed between January 2003 and December 2019. Participants in Group 1 were younger at the time of diagnosis (P < 0.001) and had more frequently family members affected by T1D (P < 0.001). Diabetic ketoacidosis (DKA) was more frequent among participants in Group 2 (P = 0.014) who also had a longer duration of symptoms before diagnosis (P < 0.001) and higher HbA1c (P = 0.001) at diagnosis. The HLA genotype was not, however, directly related to the DKA frequency. The frequency of ICA (P < 0.003), IAA (P < 0.001) and IA-2A (P < 0.001) was higher in Group 1 whereas GADA were more frequent (P < 0.001) in Group 2. Group 1 had more participants with multiple autoantibodies (P = 0.027) whereas antibody negativity was more frequent in Group 2 (P = 0.003). These findings indicate disease heterogeneity in relation to both clinical disease presentation and humoral autoimmunity, in particular. This heterogeneity is, at least partly, defined by HLA class II genotypes.

留言 (0)

沒有登入
gif